Journal Article

The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia

Stephen R. Marder, Susan M. Essock, Alexander L. Miller, Robert W. Buchanan, John M. Davis, John M. Kane, Jeffrey Lieberman and Nina R. Schooler

in Schizophrenia Bulletin

Published on behalf of Maryland Psychiatric Research Center

Volume 28, issue 1, pages 5-16
Published in print January 2002 | ISSN: 0586-7614
Published online January 2002 | e-ISSN: 1745-1701 | DOI: http://dx.doi.org/10.1093/oxfordjournals.schbul.a006926
The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia

More Like This

Show all results sharing this subject:

  • Child and Adolescent Psychiatry

GO

Show Summary Details

Preview

This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.

Keywords: Schizophrenia; antipsychotics; tardive dyskinesia; evidence-based practice; clozapine

Journal Article.  0 words. 

Subjects: Child and Adolescent Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.